34.92
-0.99 (-2.76%)
| Previous Close | 35.91 |
| Open | 35.50 |
| Volume | 1,134,404 |
| Avg. Volume (3M) | 1,432,817 |
| Market Cap | 5,513,762,816 |
| Price / Earnings (Forward) | 90.91 |
| Price / Sales | 6.65 |
| Price / Book | 8.72 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -44.96% |
| Operating Margin (TTM) | -29.34% |
| Diluted EPS (TTM) | -2.52 |
| Quarterly Revenue Growth (YOY) | 19.60% |
| Total Debt/Equity (MRQ) | 753.05% |
| Current Ratio (MRQ) | 7.61 |
| Operating Cash Flow (TTM) | -345.98 M |
| Levered Free Cash Flow (TTM) | -211.82 M |
| Return on Assets (TTM) | -7.58% |
| Return on Equity (TTM) | -105.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ionis Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 98.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tweedy, Browne Co Llc | 30 Sep 2024 | 3,454,676 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 77.00 (Wells Fargo, 120.50%) | Buy |
| Median | 63.50 (81.84%) | |
| Low | 60.00 (Needham, 71.82%) | Buy |
| Average | 66.00 (89.00%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 37.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 20 Dec 2024 | 60.00 (71.82%) | Buy | 35.63 |
| 07 Nov 2024 | 60.00 (71.82%) | Buy | 38.46 | |
| Piper Sandler | 14 Nov 2024 | 62.00 (77.55%) | Buy | 37.23 |
| Wells Fargo | 07 Nov 2024 | 77.00 (120.50%) | Buy | 38.46 |
| Guggenheim | 09 Oct 2024 | 65.00 (86.14%) | Buy | 38.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |